[Studies of the relevance of the tumor marker neopterin for therapeutic decisions and follow-up of breast cancer].
The value of serum neopterin as tumour marker was verified on 104 breast cancer patients. Based on the results, neopterin cannot be recommended either for deciding treatment after primary therapy or for monitoring of breast cancer.